KLF1抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using KLF1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using KLF1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using KLF1 mouse mAb with DAB staining.    

  
  

KLF1 (Krüppel-like factor 1), also known as Erythroid Krüppel-like Factor (EKLF), is a transcription factor critical for regulating erythroid (red blood cell) development and differentiation. It belongs to the Krüppel-like family of zinc finger proteins and plays a pivotal role in activating genes involved in hemoglobin synthesis, erythroid maturation, and cell cycle regulation. KLF1 binds to specific DNA sequences, such as the CACCC box in the β-globin gene promoter, to drive expression of adult β-globin and other erythroid-specific genes.

KLF1 antibodies are essential tools for studying its function in hematopoiesis and related disorders. Researchers use these antibodies in techniques like Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and flow cytometry to detect KLF1 expression, localization, and DNA-binding activity. KLF1 mutations or dysregulation are linked to congenital anemias (e.g., CDA-IV), hereditary persistence of fetal hemoglobin (HPFH), and platelet abnormalities, making its antibodies valuable for diagnosing or modeling such conditions. Additionally, KLF1 antibodies aid in exploring its interactions with co-regulators (e.g., GATA1) and its role in stress erythropoiesis. Most KLF1 antibodies target conserved regions, such as the N-terminal transactivation domain or C-terminal zinc fingers, ensuring specificity across human and murine models. Their applications span basic research, clinical diagnostics, and therapeutic development for blood-related diseases.